Literature DB >> 7056023

Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene.

C E Inturrisi, W A Colburn, K Verebey, H E Dayton, G E Woody, C P O'Brien.   

Abstract

Plasma concentrations of propoxyphene (P) and its pharmacologically active metabolite norpropoxyphene (NP) were determined in normal subjects after single 130-mg oral doses and during and after 13 consecutive oral doses of 130 mg P, and in former heroin addicts who were maintained on 900 to 1200 mg of P per day. The data were analyzed using a first-pass elimination pharmacokinetic model. Both P and NP cumulated during repeated dosing to levels 5 to 7 times those after the first dose. In contrast, "maintenance" patients exhibited steady-state trough plasma NP cumulation that exceeded that of P by a factor of 13. Several changes in P and NP kinetics occurred during repeated dosing with P to the normal subjects: P clearance decreased from 994 to 508 ml/min, NP clearance decreased from 454 to 2210 ml/min, P half-life (t 1/2) increased from 3.3 to 11.8 hr, NP t 1/2 increased from 6.1 to 39.2 hr, and area under the concentration time curves for P and NP were doubled. These changes in kinetics during repeated dosing resulted in more extensive cumulation of P and NP than would be predicted from the single-dose kinetic profile. Changes in the extent of first-pass elimination of P result in variability in plasma P and NP that may contribute to P-induced toxicity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7056023     DOI: 10.1038/clpt.1982.25

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

Review 1.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage.

Authors:  R J Flanagan; A Johnston; A S White; P Crome
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

3.  Sex differences in susceptibility to toxic industrial chemicals.

Authors:  E J Calabrese
Journal:  Br J Ind Med       Date:  1986-09

Review 4.  Pharmacokinetics of opioids in renal dysfunction.

Authors:  G Davies; C Kingswood; M Street
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

5.  D-propoxyphene kinetics in man: significance of a deep third compartment.

Authors:  L F Gram; K Schmidt; F N Christensen; J Schou
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  D-Propoxyphene: accumulation or altered kinetics?

Authors:  W A Colburn; C E Inturrisi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Dextropropoxyphene overdose. Epidemiology, clinical presentation and management.

Authors:  A A Lawson; D B Northridge
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Nov-Dec

8.  Dextropropoxyphene kinetics after single and repeated oral doses in man.

Authors:  K Brøsen; L F Gram; J Schou; N E Larsen; P Thayssen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 9.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 10.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.